{"id":16281,"date":"2021-01-22T09:51:10","date_gmt":"2021-01-22T08:51:10","guid":{"rendered":"https:\/\/idibell.cat\/?p=16281"},"modified":"2021-01-22T09:51:30","modified_gmt":"2021-01-22T08:51:30","slug":"aptadel-nova-spinoff-de-lidibell","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2021\/01\/aptadel-nova-spinoff-de-lidibell\/","title":{"rendered":"Aptadel, nova spinoff de l\u2019IDIBELL"},"content":{"rendered":"<p><strong>Aptadel Therapeutics<\/strong> \u00e9s una empresa precl\u00ednica cofundada per l&#8217;IDIBELL enfocada a desenvolupar una nova plataforma de ter\u00e0pia dirigida contra el c\u00e0ncer. Aquesta plataforma consisteix en nanopart\u00edcules carregades amb agents terap\u00e8utics, com poden ser mol\u00e8cules d&#8217;ARN o f\u00e0rmacs quimioter\u00e0pics, dirigides a diferents tumors diana. D&#8217;aquesta manera els agents terap\u00e8utics son alliberats nom\u00e9s all\u00e0 on fa falta, evitant aix\u00ed efectes secundaris i millorant l&#8217;efectivitat de les ter\u00e0pies.<\/p>\n<p>El <strong>Dr. \u00d3scar Mart\u00ednez-Tirado<\/strong>, investigador de l&#8217;IDIBELL i cofundador de la spin-off, apunta que &#8220;<em>aquesta \u00e9s una gran oportunitat per a traslladar el coneixement acad\u00e8mic a la pr\u00e0ctica cl\u00ednica<\/em>&#8220;. El Dr. Martinez-Tirado t\u00e9 anys d&#8217;experi\u00e8ncia en la recerca del <strong>Sarcoma d&#8217;Ewing<\/strong>, amb aquesta nova tecnologia pret\u00e9n administrar ARN d&#8217;interfer\u00e8ncia a les c\u00e8l\u00b7lules tumorals que expressin EWS\/FLI1, l&#8217;oncogen responsable del desenvolupament d&#8217;aquests tumors.<\/p>\n<p>Aptadel es llan\u00e7a amb un finan\u00e7ament inicial de <strong>1,7 milions d&#8217;euros<\/strong> resultat d&#8217;una ronda d&#8217;inversi\u00f3 aixecada per l&#8217;IDIBELL. Els co-fundadors Fundaci\u00f3 Alba P\u00e9rez han aportat un fort conjunt d&#8217;inversors privats que permetran a Aptadel desenvolupar aquesta nova tecnologia per a tractar diferents tipus de c\u00e0ncer, per\u00f2 que en un inici se centrar\u00e0 en el Sarcoma d&#8217;Ewing.<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><em>Imatge: d&#8217;esquerra a dreta, Maria del Pilar Gonz\u00e1lvez Pascual i, Rafael P\u00e9rez (por parte de la Fundaci\u00f3n Alba P\u00e9rez) i els doctors Gabriel Capell\u00e0 i Oscar Mart\u00ednez Tiradoper part de Aptade Therapeutics. (cr\u00e8dit: Fundaci\u00f3 Alba P\u00e9rez)<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aptadel Therapeutics \u00e9s una empresa precl\u00ednica cofundada per l&#8217;IDIBELL enfocada a desenvolupar una nova plataforma de ter\u00e0pia dirigida contra el c\u00e0ncer<\/p>\n","protected":false},"author":8,"featured_media":16282,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[332,447,398],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-10 08:38:13","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/16281"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=16281"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/16281\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/16282"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=16281"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=16281"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=16281"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}